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Introduction: Tyrosine kinase inhibitors (TKIs) like sorafenib are important anticancer therapeutics with thus
far limited treatment response rates in cancer patients. Positron emission tomography (PET) could provide
the means for selection of patients who might beneﬁt from TKI treatment, if suitable PET tracers would be
available. The aim of this study was to radiolabel sorafenib (1) with carbon-11 and to evaluate its potential as
TKI-PET tracer in vivo.
Methods: Synthetic methods were developed in which sorafenib was labeled at two different positions,
followed by a metabolite analysis in rats and a PET imaging study in tumor-bearing mice.
Results: [methyl-11C]-1 and [urea-11C]-1were synthesized in yields of 59% and 53%, respectively, with a purity
of N 99%. The identity of the products was conﬁrmed by coinjection on HPLC with reference sorafenib. In an in
vivo metabolite analysis [11C]sorafenib proved to be stable. The percentage of intact product in blood–plasma
after 45 min was 90% for [methyl-11C]-1 and 96% for [urea-11C]-1, respectively. Due to the more reliable
synthesis, further research regarding PET imaging was performed with [methyl-11C]-1 in nude mice bearing
FaDu (head and neck cancer), MDA-MB-231 (breast cancer) or RXF393 (renal cancer) xenografts. Highest
tracer accumulation at a level of 2.52 ± 0.33 %ID/g was observed in RXF393, a xenograft line extensively
expressing the sorafenib target antigen Raf-1 as assessed by immunohistochemistry.
Conclusion: In conclusion, we have synthesized [11C]sorafenib as PET tracer, which is stable in vivo and has the
capability to be used as PET tracer for imaging in tumor-bearing mice.
© 2013 Elsevier Inc. All rights reserved.1. Introduction
Receptor tyrosine kinases (RTKs) play a pivotal role in the signal
transduction of vital processes of the cell, for example, cell growth,
survival and proliferation. Uncontrolled activation of these receptors
is often related to tumor formation and therefore RTKs have become
important drug targets in the treatment of cancer [1–3]. To date, 12
small-molecule TKIs have been approved by the Food and Drug
Administration (FDA) and dozens are under clinical investigation
by pharmaceutical industry [4]. Despite the fact that these small-
molecule TKIs are FDA approved, the overall response rates with these
agents are low with percentages varying between 10% and 30% [5].cine and PET Research, Radio-
an1085C, 1081 HV Amsterdam,
l rights reserved.In general, no tests are available to predict who of the patients will
respond to therapy, except for the EGFR inhibiting TKIs geﬁtinib and
erlotinib for which EGFR mutation status has been associated with
effectiveness in, for example, non-small cell lung cancer (NSCLC).
However, for assessment of RTK expression and/or mutation status a
tumor biopsy has to be taken, which is not always possible. Evenwhen
a biopsy is available, it is questionable whether this is sufﬁcient to
obtain a representative overview of the whole (often heterogeneous)
tumor. Moreover, it is possible that expression and/or mutation status
differ in primary tumor and metastatic lesions or change during the
course of disease, for example upon chemo- or radiotherapy. Finally,
even when the particular RTK is abundantly expressed, this does not
guarantee efﬁcient targeting by the TKI. Taking this into account, it
might be that PET imaging with the radiolabeled TKIs itself gives a
more comprehensive overview of RTK status and the interaction of
the drug with this receptor. By radiolabeling TKIs with 18F or 11C,
these compounds can be used as PET tracer to follow the in vivo
biodistribution and tumor targeting [5,6], and ultimately to increase
the percentage of effective treatments. Recently several TKIs have
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[18F]geﬁtinib [10,11], [18F]sunitinib [12], [11C]erlotinib [13], [18F]
lapatinib [14] and [11C]sorafenib [15]. Unfortunately, thus far only
[11C]geﬁtinib, [18F]geﬁtinib and [11C]erlotinib have been used in
suitable preclinical studies for in vivo tumor targeting, in which [11C]
erlotinib displayed the most promising results [5]. In fact, [11C]
erlotinib has been applied in cancer patients already and did show its
value for patient selection [16–18].
Sorafenib (Nexavar®, Bayer Pharmaceuticals) is an orally
administered multi-kinase inhibitor for the treatment of patients
with unresectable hepatocellular carcinoma (HCC) or with advanced
renal cell carcinoma (RCC) [19]. Moreover, sorafenib is under
investigation as monotherapy or combination therapy in phase II/
III clinical trials for the treatment of various other types of cancer.
Despite the fact that sorafenib is FDA approved, the overall response
rate with this drug in the indicated patient population is still low
[20,21]. Originally, sorafenib was discovered during a high-through-
put screening as selective inhibitor of the Raf-1 kinase. Later on, it
was proven in in vitro assays that sorafenib inhibits at least
10 kinases in the lower nM range, among which Raf-1 kinase
IC50 = 6 nM, wild-type B-Raf IC50 = 25 nM and VEGFR1 IC50 =
26 nM as preferred targets [22].
Our research aimed at the development of two reliable synthesis
routes to obtain [methyl-11C]-1 or [urea-11C]-1 (Fig. 1) and the
preclinical evaluation of these PET tracers in vivo. The synthesis of
[urea-11C]-1 has been published before by the use of [11C]COCl2 [15].
As an alternative for facilities that lack the presence of [11C]COCl2,, we
herein describe a novel method to produce [urea-11C]-1 using a
rhodium-mediated reaction between a precursor azide and amine in
the presence [11C]CO [23]. Next to that, a second labeling strategy will
be described to obtain [methyl-11C]-1, using a straightforward
methylation of an amide with [11C]methyl iodide [24] of the
desmethyl precursor. Furthermore, the metabolic stability of both
tracers was investigated in rats, while the tumor targeting potential of
one of these tracers was evaluated in nude mice bearing three
different xenograft lines that had been immunohistochemically
characterized for Raf-1 kinase and CD31 expression.Fig. 1. Broad-spectrum TKI sorafenib 1 and two desired PET tracers being [methyl-11C]-1
and [urea-11C]-1.2. Materials and methods
2.1. General
All reactions were carried out at ambient temperature and all
reagents and solvents were supplied by Aldrich Chemical Co., Fluka,
ABCR, Acros or Biosolve BV, and used as received unless stated
otherwise. Rf values were determined by thin layer chromatography
(TLC) on Merck precoated silica gel 60 F254 plates. Spots were
visualized by UV-quenching, ninhydrin, KMnO4, vanillin or TDM-Cl2.
Column chromatography was carried out by using Silica gel 60 Å
(Sigma-Aldrich/Merck). 1H NMR spectra were recorded on a Bruker
Avance 250 (250.13 MHz) with chemical shifts (δ) reported in ppm
relative to the solvent (7.26 ppm for CDCl3 and 2.50 ppm for DMSO-
d6). 13C NMR spectra were recorded by using the attached proton test
(APT) sequence on a Bruker Avance 250 (62.90 MHz) spectrometer
and chemical shifts are given in ppm relative to TMS by using the
residual proton signal (77.0 ppm for CDCl3 and 39.5 ppm for DMSO-
d6). Infrared (IR) spectra were obtained using a Shimadzu FTIR-
8400S, wavelengths (ν) are reported in cm−1. Electrospray ionization
mass spectrometry (ESI-MS) was carried out using a Bruker micrO-
TOF-Q instrument in positive ion mode (capillary potential
of 4500 V). Analytical HPLC was performed on a Jasco PU-2089 Plus
Quaternary Gradient Pump. Analytical isocratic HPLC was carried
out with a reverse-phase C18 column (C18 Platinum 5 μm
250 mm × 4.6 mm; Eluent: MeCN/H2O/TFA, 60:40:0.1, v/v/v; k =
254 nm) as eluent at a ﬂow rate of 1 mL · min−1, a Jasco UV-2075
Plus UV detector and a NaI radioactivity detector (Raytest, Strauben-
hardt, Germany). Semi-prep isocratic HPLC was carried out with a
reverse-phase C18 column (Grace AlltimaTM C18 5 μm
250 mm × 10 mm) using H2O/MeCN/TFA (59:41:0.1, v/v/v) as eluent
at a ﬂow rate of 5 mL · min−1, a Jasco UV1575 UV detector (254 nm)
and a custom-made radioactivity detector. Analytical HPLC for
metabolite analysis was carried out with a Phenomenex Luna C18
column (5 μm 250 mm × 10 mm) using a gradient of 90% buffer A
(MeCN) to 90% buffer B (H2O/TFA, 99.9:0.1, v/v) in 12 min at a ﬂow
rate of 4 mL · min−1.
2.2. Chemistry
2.2.1. BOC-4-aminophenol
4-Aminophenol (4.0 g, 37 mmol) was dissolved in H2O/THF
(100 mL, 1:1, v/v) and at 0 °C BOC2O (8.8 g, 40.4 mmol) and
NaHCO3 (3.4 g, 40.4 mmol) were added. The mixture turned purple
and was allowed to stir at RT for 5 h. The reaction mixture was
concentrated in vacuo. The residue was dissolved in EtOAc and
washed with H2O (3 × 50 mL), 1 M KHSO4 (3 × 50 mL), and brine
(50 mL). The organic phase was dried on Na2SO4 and evaporated to
dryness yielding BOC-4-aminophenol (10.7 g, quant.) as a white solid.
Rf = 0.57 (EtOAc/hexanes, 1:2, v/v); 1H NMR (250 MHz, DMSO-d6): δ
9.00 (s, 1H, OH), 8.94 (bs, 1H, NH), 7.22 (d, 2H, J = 8.8 Hz, ArH2,6),
6.65 (d, 2H, J = 8.9 Hz, ArH3,5), 1.46 (s, 9H, C(CH3)3); 13C-NMR
(63 MHz, DMSO-d6): δ 153.0 (C = O), 152.5 (ArCOH), 131.0 (ArCNH),
120.0, 115.0 (ArCH), 78.4 (C(CH3)3), 28.2 (C(CH3)3).
2.2.2. 4-Chloropicolinamide (3)
Picolinic acid (1.23 g, 10 mmol) was added in small portions at
45 °C to a solution of DMF (0.13 mL, 2.5 mmol) in SOCl2 (5.95 g,
50 mmol). Picolinic acid dissolved slowly and the mixture was
allowed to stir at 72 °C for 16 h. The reaction mixture was cooled to
RT and concentrated in vacuo followed by coevaporation with CH2Cl2
(2 × 10 mL). The orange solid was suspended in CH2Cl2 (25 mL) and
gaseous NH3 was slowly led through the reaction mixture for 1 h. The
reaction mixture was evaporated to dryness. The residue was
dissolved in CH2Cl2 (150 mL) and washed with sat. aq. NaHCO3
(50 mL) and the aqueous layer was extracted with CH2Cl2
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and evaporated to dryness. The crude product was puriﬁed using
column chromatography (EtOAc/hexanes, 2:1, v/v) yielding 3
(832 mg, 5.3 mmol, 53%) as an off-white solid. Rf = 0.62 (EtOAc/
hexanes, 3:1, v/v); 1H-NMR (250 MHz, CDCl3): δ 8.53 (d, 1H, Jortho =
5.2 Hz, ArH6), 8.27 (d, 1H, Jmeta = 1.9 Hz, ArH3), 7.86 (bs, 1H, NH),
7.51 (dd, 1H, Jmeta = 2.1, J = 5.3 Hz, ArH5), 5.91 (bs, 1H, NH); 13C-
NMR (63 MHz, CDCl3): δ 165.6 (C = O), 151.0 (ArC), 149.2 (ArCH),
146.0 (ArC), 126.7 (ArCH), 123.2 (ArCH) ppm.
2.2.3. BOC-4-(4-aminophenoxy)picolinamide (4)
NaOH pallets (192 mg, 4.8 mmol) were added to a solution of 4-
chloropicolinamide 3 (250 mg, 1.6 mmol) and BOC-4-aminophenol
(480 mg, 2.3 mmol) in DMF. The reaction mixture was allowed to stir
for 16 h at 80 °C. The mixture was evaporated to dryness, dissolved in
EtOAc (50 mL) and washed with brine (3 × 25 mL). The organic
phase was dried on Na2SO4 and concentrated in vacuo. The crude
product was puriﬁed using column chromatography (EtOAc/hexanes,
1:1 v/v) yielding 4 (100 mg, 0.31 mol, 19%) as a white solid. Rf = 0.24
(EtOAc/hexanes, 1:1, v/v); 1H-NMR (250 MHz, CDCl3): δ 8.45 (d, 1H,
Jortho = 5.6 Hz, ArH), 7.97 (bs, 1H, NH), 7.75 (d, 1H, Jmeta = 2.5 Hz,
ArH), 7.48 (d, 2H, Jortho = 8.9 Hz, ArH), 7.05 (m, 3H, ArH), 6.64 (bs,
1H, NH-BOC), 5.68 (bs, 1H, NH), 1.58 (s, 9H, C(CH3)3); 13C-NMR
(63 MHz, CDCl3): δ 167.4, 165.3 (C = O), 152.8 (ArC), 151.0 (ArC),
149.3 (ArCH), 148.5 (ArC), 136.6 (ArC), 121.4 (ArCH), 120.4 (ArCH),
114.5 (ArCH), 111.1 (ArCH), 80.8 (C(CH3)3), 28.4 (C(CH3)3) ppm.
2.2.4. Desmethylsorafenib (6)
BOC-4-(4-aminophenoxy)picolinamide 4 (220 mg, 0.67 mmol)
was dissolved in a mixture of CH2Cl2/TFA (6 mL, 1:1, v/v) and stirred
for 1 h at RT. The mixture was concentrated in vacuo, dissolved in
EtOAc (20 mL) and washed with aq. sat. NaHCO3 (3 × 25 mL). The
organic solution was dried on Na2SO4 and evaporated to dryness to
yield 5 quantitatively. The deprotected product was dissolved in
CH2Cl2 (10 mL) and to this solution 4-chloro-3-triﬂuoromethyl
phenyl isocyanate (73 mg, 3.3 mmol) was added and the reaction
mixture was stirred at RT for 72 h. The solution was concentrated in
vacuo. The crude product was puriﬁed using column chromatography
(EtOAc/toluene, 1:1, v/v) yielding 6 (120 mg, 0.27 mmol, 40%) as
white solid. Rf = 0.54 (EtOAc/MeOH, 98:2, v/v); 1H-NMR (250 MHz,
DMSO-d6): δ 9.23 (s, 1H, NH), 9.00 (s, 1H, NH), 8.52 (d, 1H, Jortho =
5.6 Hz, ArH), 8.13 (m, 2H, NH, ArH), 7.64 (m, 5H, NH, 4x ArH), 7.40 (d,
1H, Jmeta = 2.5 Hz, ArH), 7.17 (m, 3H, 3x ArH) ppm. 13C-NMR
(125 MHz, DMSO-d6): δ 166.4 (C = O), 165.9 (C = O), 153.1 (ArC),
152.9 (ArC), 150.9 (ArCH), 148.3 (ArC), 139.7 (ArC), 137.5 (ArC),
132.4 (ArCH), 127.1 (q, ArCCF3), 123.6 (ArCH), 123.3 (q, CF3), 122.8
(ArC), 121.9 (ArCH), 120.9 (ArCH), 117.3 (ArCH), 114.6 (ArCH),
109.2 (ArCH) ppm. HRMS calcd. for C20H15N4O3: 450.0785, found:
451.0755 [M + H]+.
2.2.5. 4-Chloropicolinic-methylester (7)
Picolinic acid (1.23 g, 10 mmol) was added in small portions at
45 °C to a solution of DMF (0.13 mL, 2.5 mmol) in SOCl2 (5.95 g,
50 mmol). Picolinic acid dissolved slowly and the mixture was
allowed to stir at 72 °C for 16 h. The reaction mixture was cooled to
RT and concentrated in vacuo followed by coevaporation with toluene
(3 × 10 mL). The orange residue was dissolved in MeOH (30 mL),
stirred at RT for 1 h and concentrated in vacuo. The residue was
dissolved in EtOAc (150 mL) and washed with sat. aq. NaHCO3
(2 × 50 mL), H2O (2 × 50 mL) and brine (50 mL). The organic layer
was dried on Na2SO4 and evaporated to dryness. The crude product
was puriﬁed using column chromatography (EtOAc/hexanes, 1:1, v/v)
yielding 7 (1.2 g, 7.1 mmol, 71%) as white solid. Rf = 0.54 (EtOAc/
hexanes, 1:1, v/v); 1H-NMR (250 MHz, CDCl3): δ 8.65 (d, 1H, Jortho =
5.2 Hz, ArH6), 8.15 (d, 1H, Jmeta = 2.0 Hz, ArH3), 7.51 (dd, 2H, Jmeta =
1.9 Hz, Jortho = 5.2 Hz, ArH5), 4.03 (s, 3H, CH3) ppm; 13C-NMR(CDCl3, 63 MHz): 13C-NMR (63 MHz, CDCl3): δ 164.6 (C = O),
150.6 (ArCH), 149.2 (ArC), 145.6 (ArC), 127.2 (ArCH), 125.7 (ArCH),
53.2 (OCH3) ppm.
2.2.6. 4-Chloropicolin-methylamide (8)
A solution of DiPEA (5.2 g, 40 mmol) in THF (5 mL) was added to a
solution of 4-chloropicolinic-methylester 7 (684 mg, 4 mmol) and
methylamine · HCl (2.7 g, 40 mmol) in THF (20 mL). The mixture
was stirred at RT for 72 h and concentrated in vacuo. The residue was
dissolved in EtOAc (50 mL), washed with brine (2 × 50 mL) and
dried on Na2SO4. The organic solution was evaporated to dryness
yielding 8 (606 mg, 3.6 mmol, 89%) as a yellow oil. Rf = 0.55 (EtOAc/
hexanes, 3:1, v/v); 1H-NMR (250 MHz, CDCl3): δ 8.45 (d, 1H, Jortho =
5.2 Hz, ArH6), 8.23 (d, 1H, Jmeta = 2.0 Hz, ArH3), 8.00 (bs, 1H, NH),
7.45 (dd, 1H, Jmeta = 2.1 Hz, Jortho = 5.2, ArH5), 3.0 (d, 3H, J =5.1 Hz,
CH3); 13C-NMR (63 MHz, CDCl3): δ 163.7 (C = O), 151.4 (ArC), 149.0
(ArCH), 146.0 (ArC), 126.3 (ArCH), 122.8 (ArCH), 26.2 (NHCH3) ppm.
2.2.7. BOC-4-(4-aminophenoxy)picolin-methylamide (9)
NaOH pallets (21 mg, 0.53 mmol) were added to a solution of 4-
chloropicolin-methylamide 8 (85 mg, 0.5 mmol) and BOC-4-amino-
phenol (114 mg, 0.5 mmol) in DMF. The reaction mixture was
allowed to stir for 16 h at 80 °C. The mixture was evaporated to
dryness, dissolved in EtOAc (50 mL) and washed with brine
(3 × 25 mL). The organic phase was dried on Na2SO4 and concen-
trated in vacuo. The crude product was puriﬁed using column
chromatography (EtOAc/hexanes, 3:2, v/v) yielding 9 (32 mg, 19%)
as a colorless oil. Rf = 0.12 (EtOAc/hexanes, 2:1, v/v); 1H-NMR
(250 MHz, CDCl3): δ 8.41 (d, 1H, Jortho = 5.7 Hz, ArH), 8.15 (bs, 1H,
NH), 7.76 (d, 1H, Jmeta = 2.5 Hz, ArH), 7.48 (dd, 2H, Jmeta = 2.1 Hz,
Jortho = 6.8 Hz, ArH), 7.09 (d, 2H, Jmeta = 2.2 Hz, ArH), 6.99 (dd, 1H,
Jmeta = 2.6 Hz, Jortho = 5.7 Hz, ArH), 6.62 (bs, 1H, NH), 3.06 (d, 3H,
J = 5.1 Hz, CH3), 1.58 (s, 9H, CH3); 13C-NMR (63 MHz, CDCl3): δ
166.9, 164.3 (C = O), 152.8, 152.0, 149.3, 148.7, 136.4, 121.4, 120.4,
113.9, 110.4, 80.7(C(CH3)3), 28.3 (C(CH3)3), 26.2 (NHCH3) ppm.
2.2.8. 4-(4-Aminophenoxy)picolin-methylamide (10)
BOC-4-(4-aminophenoxy)picolin-methylamide 9 (250 mg,
0.73 mmol) was dissolved in a mixture of CH2Cl2/TFA (6 mL, 1:1,
v/v). After stirring for 1 h at room temperature the mixture was
concentrated in vacuo. The remaining residue was dissolved in EtOAc
(50 mL), washed with aq. sat. NaHCO3 (50 mL), dried on Na2SO4 and
evaporated to dryness. The crude product was puriﬁed using column
chromatography (EtOAc/hexanes, 2:1, v/v) yielding 10 (160 mg, 90%)
as a light brown oil. Rf = 0.49 (CH2Cl2/MeOH, 9:1, v/v); 1H-NMR
(250 MHz, CDCl3): δ 8.37 (d, 1H, Jortho = 5.7 Hz, ArH), 8.04 (bs, 1H,
NH), 7.71 (d, 1H, Jmeta = 2.5 Hz, ArH), 6.95 (dd, 1H, Jmeta = 2.6 Hz,
Jortho = 5.6 Hz ArH), 6.91 (dt, 2H, Jmeta = 3,2 Hz, Jortho = 8,6 Hz,
2 × ArH), 6.74 (dt, 2H, Jmeta = 3,3 Hz, Jortho = 8,8 Hz, 2 × ArH), 3.76
(bs, 2H, NH2), 3.03 (d, 3H, J = 5.1 Hz, CH3), 13C-NMR (125 MHz,
CDCl3): δ 167.3 (C = O), 164.8 (ArC), 152.2 (ArC), 149.6 (ArCH), 145.6
(ArC), 144.5 (ArC), 122.0 (ArCH), 116.5 (ArCH), 113.8 (ArCH), 110.0
(ArCH), 26.2 (NHCH3) ppm. HRMS calcd. for C13H13N3O2: 243.1008,
found: 244.1081 [M + H]+, 266.0888 [M + Na]+.
2.2.9. 4-(4-Azidophenoxy)picolin-methylamide (11)
tert-Butyl nitrite (0.09 mL, 0.7 mmol) at 0 °C was slowly added to
a solution of 4-(4-aminophenoxy)picolin-methylamide (115 mg,
0.47 mmol) in MeCN (2 mL) and stirred for 15 min. Trimethylsilyl
azide (0.08 mL, 0.6 mmol) was added and stirred at RT for 16 h. The
reaction mixture was evaporated in vacuo and puriﬁed using
column chromatography (EtOAc/hexanes, 1:1, v/v) yielding 4-(4-
azidophenoxy)picolin-methylamide 11 as an off-white solid. FTIR
(ATR, cm−1): 2102 (N3); 1H-NMR (250 MHz, CDCl3): δ 8.24 (d, 1H,
Jortho = 5.6 Hz, ArH), 7.90 (bs, 1H, NH), 7.55 (d, 1H, Jmeta = 2.5 Hz,
ArH), 6.84 (s, ArH), 6.81 (dd, 1H, Jmeta = 2.5 Hz, Jortho = 5.6 Hz, ArH),
491A.J. Poot et al. / Nuclear Medicine and Biology 40 (2013) 488–4972.86 (d, 3H, Jortho = 5.1 Hz, NHCH3) ppm; 13C-NMR (63 MHz, CDCl3):
δ 166.1 (C = O), 164.4 (ArC), 152.4 (ArC), 150.7 (ArC), 149.7 (ArCH),
137.5 (ArC), 122.3 (ArCH), 120.8 (ArCH), 114.1 (ArCH), 110.0 (ArCH),
26.1 (NHCH3) ppm.
2.2.10. 4-Chloro-3-trifuoromethyl phenyl azide (14)
tert-Butyl nitrite (0.36 mL, 3 mmol) and trimethylsilyl azide
(0.32 mL, 2.4 mmol) were slowly added to a solution of 4-chloro-3-
triﬂuoromethyl aniline (400 mg, 2 mmol) in 5 mL acetonitrile at 0 °C.
The reaction mixture was allowed to reach RT and stirred for 1 h
followed by concentration in vacuo. The crude product was puriﬁed
by silica column chromatography (hexane) to yield 14 as yellow oil
(312 mg, 70%). Rf = 0.80 (hexanes); FTIR (ATR, cm−1): 2112.1 (N3);
1H-NMR (250 MHz, CDCl3): δ 7.53 (d, 1H, Jortho = 8.6 Hz, ArH2), 7.37
(d, 1H, Jmeta = 2.7 Hz, ArH5), 7.19 (dd, 1H, Jmeta = 2.7 Hz, Jortho =
8.6 Hz, ArH3) ppm; 13C-NMR (63 MHz, CDCl3): δ 139.4 (ArCN3), 132.8
(ArCH), 130.1 (q, ArCCF3), 128.0 (ArCCl), 123.0 (ArCH), 120.1 (q, CF3),
118.4 (q, ArCH) ppm; 19F-NMR (CDCl3): −63.16 (CF3) ppm.
2.3. Radiosynthesis
2.3.1. [methyl-11C]sorafenib([methyl-11C]-1)
Carried by a helium stream (10 mL/min), [11C]CO2 was bubbled
through a solution of 100 μL 0.1 M LiAlH4 in THF at 20 °C. The solution
was dried by heating the reaction vial to 130 °C under a stream of
helium. To the residue was added 0.22 mL 60% HI in water. The
formed [11C]CH3I was distilled through a sicapent/NaOH column to a
second reaction vial containing a solution of desmethyl sorafenib 6
(1 mg, 2.2 μmol) and TBAOH (1 μL, 2 μmol, 60% solution in water) in
DMF (110 μL). The reactionmixturewas heated at 80 °C for 3 min and
diluted with 2 mL of semi-prep HPLC eluent and subjected to semi-
prep HPLC puriﬁcation (Alltima C18 column; eluent: MeCN/H2O/TFA,
60:40:0.1, v/v/v). The fraction containing [methyl-11C]-1 (Rt =
8.6 min) was collected, diluted with water (60 mL) and trapped on
a Sep-Pak C18 plus cartridge. The product was washed with water
(20 mL), eluted with EtOH (1 mL) and diluted with 2.5% polysorba-
tum 80 in saline (9 mL). The decay-corrected radiochemical yield
calculated from EOB of [methyl-11C]-1 was 60% ± 7%. The speciﬁc
activity was 150–210 GBq/μmol at the end of synthesis after
formulation. The overall synthesis time from EOB was ± 35 min.
2.3.2. [urea-11C]sorafenib([urea-11C]-1)
Carried by a stream of helium (20 mL/min) [11C]CO2 passed over
Zinc at 400 °C. The formed [11C]CO was ﬁrst passed through an
ascarite column (to trap unreacted [11C]CO2) and then concentrated
on a liquid nitrogen-cooled silica containing trap of approximately
50 μL. The concentrated [11C]CO was then released by instant heating
of the trap and pushed into a in a micro-autoclave with a helium ﬂow
(20 mL/min). A solution of 4-chloro-3-triﬂuoromethyl phenyl azide
14 (6.7 mg, 30 μmol), 4-(4-aminophenoxy)picolin-methylamide 10
(15 mg, 61 μmol, Rh(I)chloro(1,5-cyclooctadiene) (0.5 mg, 1 μmol)
and PPh3 (0.5 mg, 2 μmol) in 400 μL distilled THF was added to the
micro-autoclave using an HPLC-pump until a pressure of 350 bar was
reached The reaction mixture was heated at 120 °C for 5 min and
collected in a vial for puriﬁcation. The crude mixture was diluted with
2 mL of semi-prep HPLC eluent and subjected to HPLC puriﬁcation
(Alltima C18 column; eluent: MeCN/H2O/TFA, 55:45:0.1, v/v/v). The
fraction containing [urea-11C]-1 (Rt = 11.5 min) was collected,
diluted with water (60 mL) and trapped on a Sep-Pak C18 plus
cartridge. The product was washed with water (20 mL), eluted with
EtOH (1 mL) and diluted with 2.5% polysorbatum 80 in saline (9 mL).
The decay-corrected radiochemical yield calculated from end of
bombardment (EOB) of [urea-11C]-1 was 27% ± 11%. The speciﬁc
activity was 30–50 GBq/μmol at the end of synthesis after formulation
and the overall synthesis time from EOB was ± 50 min.For both [urea-11C]-1 and [methyl-11C]-1 radiochemical purities
were determined to be over 99%. The identity of the product was
checked by analytical HPLC (after coinjection of the products with
unlabeled sorafenib (Rt = 6.8 min on Platinum C18 column; eluent:
MeCN/H2O/TFA, 60:40:0.1, v/v/v) and (Rt = 9.9 min on Alltima C18
column; eluent: MeCN/H2O/TFA, 60:40:0.1, v/v/v).
2.4. Metabolite analysis
In order to determine the efﬁciency of the workup procedure and
the HPLCmethod, the trapping and elution of the radioactive products
from the tC18 Sep-Pak cartridge (Waters, the Netherlands) and the
HPLC were determined prior to the metabolite analysis experiments
and found to be N 95%. Four male Wistar rats were injected with 100–
150 MBq of either [urea-11C]-1 or [methyl-11C]-1, in the tail vein
under isoﬂurane anesthesia (2% in 1 L · min−1). These rats were
sacriﬁced at 15 (N = 2 per tracer) and 45 (N = 2 per tracer) min
post-injection. At these time points, 2 mL of blood was collected via a
heart puncture. Blood was collected in a heparin tube and centrifuged
for 5 min at 4000 RPM (Hettich universal 16, Depex B.V., the
Netherlands). Plasma was separated from blood cells and 1 mL of
plasma was diluted with 2 mL of water and loaded onto a tC18 Sep-
Pak cartridge, which was pre-activated by elution of 6 mL of MeOH
and 12 mL of water, respectively. The cartridge was washed with
3 mL of H2O to collect polar radioactive metabolites. Thereafter, the
tC18 Sep-Pak cartridge was eluted with 2 mL of MeOH and 1 mL of
H2O to collect themixture of apolarmetabolites. Themixture of apolar
metabolites was analyzed using HPLC to determine the percentage of
intact [urea-11C]-1 or [methyl-11C]-1.
2.5. Immunohistochemical staining
Sections of frozen xenografts (RXF393, FaDu and MDA-MB-231)
were immunostained for assessment of Raf-1 kinase and CD31
expression. Frozen tissue sections were ﬁxed for 10 min in 2%
paraformaldehyde and pre-incubated for 30 min with 2% normal
swine serum for Raf-1 or normal rabbit serum for CD31 (Dako,
Enschede, the Netherlands). Primary antibodies were incubated for
1 h at RT [(anti-Raf1, AB18761 (ITK Diagnostics BV, Uithoorn, the
Netherlands) and rat-anti-mouse CD31 (BD Pharmingen, Breda, the
Netherlands)]. A horseradish peroxidase-conjugated swine–anti-
rabbit (Dako, Enschede, the Netherlands) was used as a secondary
antibody for Raf-1. For CD31 a horseradish peroxidase-conjugated
mouse–anti-rat (Life Technologies Europe BV Bleiswijk) was used.
The staining was developed with diaminobenzidine and H2O2 as
chromogen. The sections were counterstained with hematoxylin and
coverslipped with Kaiser's glycerin.
2.6. PET imaging with [methyl-11C]-1
Dynamic PET imaging was performed on three cancer xenograft
lines in nude mice. Each mouse (N = 2) carried two tumors of the
same cancer xenograft line (RXF393, FaDu or MDA-MB-231), which
were located on the left and right ﬂank. Imaging was performed for a
duration of 90 min using a double-LSO/LYSO layer high-resolution
research tomograph (HRRT; CTI/Siemens, Knoxville, TN, USA). The
mice were anesthetized with 4% and 2% isoﬂurane in 1 L · min−1
oxygen for induction and maintenance, respectively. First, for
attenuation and scatter correction, a transmission scan was acquired
using a 740-MBq two-dimensional (2D) fan-collimated 137Cs
(662 keV) moving point source. Next, a dynamic emission scan
was acquired immediately following administration of 10 MBq
[methyl-11C]-1 (SA 54–241 GBq/μmol) to each animal. Positron
emission scans were acquired in list mode and rebinned into the
following frame sequence: 12 × 10, 2 × 30, 2 × 60, 2 × 150,
2 × 300 and 4 × 600 s. After 90 min, [18F]FDG was administered
492 A.J. Poot et al. / Nuclear Medicine and Biology 40 (2013) 488–497to the mice followed by scanning for another 60 min. Following
corrections for decay, dead time, scatter and randoms, scans were
reconstructed using an iterative 3D ordered-subsets weighted least-
squares analysis (3D-OSWLS). Point source resolution varied across
the ﬁeld of view from approximately 2.3 to 3.2-mm full width at half
maximum in the transaxial direction and from 2.5 to 3.4 mm in the
axial direction. No post-ﬁltering or smoothing of the images was
performed during or after reconstruction. The PET images were
analyzed using the freely available AMIDE-software version 0.9.3
(A Medical Imaging Data Examiner). A box was drawn over the
complete animal to obtain the image-derived injected dose (IDID).
ROIs containing the tumor tissue as well as a reference area, which is
tissue closely located to the tumor without only containing muscle
and skin, were drawn using the [18F]FDG data followed by an overlay
of these images with the corresponding [methyl-11C]-1 images. A
time activity curve was plotted for both the tumor as well as the
reference area.
2.7. Biodistribution of [methyl-11C]-1
Nudemice carrying two tumors of the same xenograft line on their
left and right ﬂank (RXF393, FaDu or MDA-MB-231), received an
injection of 25–50 MBq [methyl-11C]-1 via the tail vein. Themice were
sacriﬁced and dissected at 5, 30 and 60 min post-injection. Blood,
urine, skin, left tumor, right tumor, muscle, heart, lung, liver, kidney
and brain were collected, weighed and counted for radioactivity on a
Wallac Compugamma 1210 (N = 3 for each time point). Biodistribu-
tion data are expressed as percentage of injected dose per gram
(%ID/g) tissue.
2.8. Statistical analysis
For PET imaging results, the differences in [methyl-11C]-1 uptake in
tumor compared to reference tissue were statistically analyzed for
each xenograft at each different time point with Statistica
software (Statsoft Inc., France). Differences in tumor uptake compared
to reference tissue over time were analyzed using a repeated-
measure ANOVA.
For data obtained from the biodistribution experiments, the
differences in tumor and normal organ uptake of [methyl-11C]-1
were statistically analyzed for the three xenograft lines tested with
Statistica software (Statsoft Inc.). A factorial ANOVA for the factors,
tissue uptake, tumor type and time were used for the quantitativeScheme 1. Synthesis of 6 as precursor for rmeasure of [methyl-11C]-1 uptake. When ANOVA yielded signiﬁcant
effects, Fisher–LSD posttests were used to investigate differences in
uptake between tumor types at the different time points.3. Results and discussion
3.1. Chemistry and radiochemistry
The synthesis of precursor 6 for radiolabeling to obtain
[methyl-11C]-1 proved to be straight forward, moderate to high
yielding and all desired products could be synthesized according to
literature procedures except for the Williamson ether synthesis to
obtain 4 [25]. The synthesis of precursor 6 started with commercially
available picolinic acid 2, which was converted to the intermediate
acyl-chloride in thionyl chloride and a catalytic amount of DMF, which
was without workup reacted with gaseous ammonia to yield the
desired amide 3. Initially, literature procedures were followed using
commercially available unprotected 4-amino phenol that could be
coupled to aryl-chloride 3 using KOtBu as a base for deprotonation
[25]. Despite various attempts using other bases like NaOH, KOH and
n-BuLi, no desired product was obtained in this reaction. Key was the
protection of the amine using a BOC-protecting group, which resulted
in the successful formation of compound 4. Therefore, amide 3 was
reacted with BOC-protected aminophenol in a Williamson ether
synthesis to afford 4 in an average yield of 19%. Unfortunately, despite
further attempts to optimize the reaction conditions, yields could not
be further improved. Subsequently, the BOC-protecting group of 4
was removed by treatment with TFA. Without additional puriﬁcation
the crude product was reacted with 4-chloro-3-triﬂuoromethylphe-
nyl isocyanate in DCM to obtain desired precursor 6 in a yield of
40% (Scheme 1).
The radiolabeling to synthesize [methyl-11C]-1 by methylation
with [11C]CH3I of precursor molecule 6 is outlined in Scheme 3.
Successful radiolabeling was achieved by conversion of [11C]CO2 to
[11C]CH3I as alkylating agent treatment. [11C]CO2 was reduced to the
lithium methoxide salt by treatment with LiAlH4 in THF followed by
halogenation to obtain [11C]CH3I with a 60% HI solution in water [24].
The formed [11C]CH3I was then distilled to the reaction vial containing
precursor 6, which was dissolved in DMF in the presence of TBAOH
(Scheme 3A) for 3 min at 80°. The crude radiolabeling reaction
mixture was puriﬁed by semi-preparative HPLC and the labeling yield
of the desired product [methyl-11C]-1 was on average 60% decayadiolabeling to obtain [methyl-11C]-1.
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optimization was required.
Additionally, the radiolabeling to synthesize [urea-11C]-1 has been
explored and to achieve successful radiolabeling two methods have
been investigated. The ﬁrst method investigated was a reaction
between an amine and a triphenylphosphinimine in the presence of
[11C]CO2, a method that has been developed by van Tilburg et al. [26].
Secondly procedures as described by were explored, which is a
rhodium-mediated reaction between an azide and an amine in the
presence of [11C]CO.
The initial method exploited to obtain [urea-11C]-1 was the
reaction between an amine and a triphenylphosphinimine in the
presence of [11C]CO2 [26]. The two possibilities to obtain the ﬁnal
desired product are a reaction between amine 10 with triphenylpho-
sphinimine 15 or amine 13 with triphenylphosphinimine 12
(Scheme 3). The required precursors were synthesized from com-
mercially available picolinic acid 2. Therefore, picolinic acid 2 was
converted to the intermediate acyl-chloride using thionyl chloride
and a catalytic amount of DMF followed by quenching of the reaction
mixture with methanol to obtain in methyl ester 7. Compound 7 was
converted to methylamide 8 by a nucleophilic substitution with
methylamine at room temperature in a THF/MeOH solution followed
by the previously described Williams ether synthesis to obtain BOC-
protected diaryl ether 9. Then, deprotection of compound 9 resulted
in the desired amine and precursor 10. Furthermore, amine 10 was
converted to azide 11 using tert-butyl nitrite and trimethylsilyl azide,
and desired precursor 12 was obtained upon treatment with
triphenylphosphine (Scheme 2A). Precursor molecule 13 was com-Scheme 2. Synthesis of precursors for radiolabmercially available and was converted to azide 14 in 70% yield by the
treatment with tert-butyl nitrite and trimethylsilyl azide. Precursor
15 was obtained in high yield from azide 14 after treatment with
triphenylphosphine. In general the synthesis to obtain precursors,
10, 12 and 15 proved to be straight forward and all desired
compounds were obtained in moderate to high yields. Only during
the Williamson ether synthesis to obtain compound 8 similar
considerations were made as previously described, resulting in the
ﬁnal use of a BOC-protected 4-amino phenol and NaOH as base for
optimal reaction conditions.
Unfortunately, in all radiolabeling attempts between 10 and 15 as
well as 12 and 13 in the presence of [11C]CO2, to obtain [urea-11C]-1,
no desired product was obtained (Scheme 3B). An explanation for
these disappointing results might be found in the poor reactivity of
the 4-chloro-3-triﬂuoromethyl phenyl derivative present in pre-
cursors 13 and 15. The strong electron withdrawing character of the
4-chloro-3-triﬂuoromethyl phenyl derivatives probably reduces the
chemical reactivity of the amine moiety and therefore hampers
desired product formation.
Therefore, to successfully achieve the synthesis of [urea-11C]-1,
procedures as described by Doi et al. [23] were explored, which is a
rhodium-mediated reaction between an azide and an amine in the
presence of [11C]CO. The two possibilities to obtain the ﬁnal desired
product are a reaction between precursors being amine 10 with azide
14 or azide 11 with amine 13 (Scheme 3B). All required precursors for
the radiolabeling of [urea-11C]-1, being amines 10 and 13 as well as
azides 11 and 14, were intermediate products from the previously
described precursor synthesis, whichwas required for the radiolabelingeling with [11C]CO to obtain [urea-11C]-1.
Scheme 3. Radiolabeling to synthesize [methyl-11C]-1 and [urea-11C]-1.
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tional precursor synthesis for radiolabeling of [urea-11C]-1 was
required. [11C]CO was prepared according to described literature
methods by Verbeek et al. [27], in which [11C]CO2 was reduced to
[11C]CO over zinc at 400 °C. The formed [11C]CO was ﬁnally trapped
in a micro-autoclave to which a mixture of amine and azide
precursors, Rh(I)chloro(1,5-cyclooctadiene) and triphenylpho-
sphine was added at a pressure of 350 bar. The 5-min heated
crude reaction mixture was puriﬁed by semi-preparative HPLC and
the labeling yield of the desired product [urea-11C]-1was on average
27% decay corrected when precursors 10 and 14 were used (n = 5)
(Scheme 3B). Performing the reaction in a reversed order with azide
11 and amine 13, to come to the [urea-11C]-1 product as well, proved
to be unsuccessful and only trace amounts of product could be
detected. Also in this case, the strong electron withdrawing nature of
the 4-chloro-3-triﬂuoromethyl phenyl moiety reduces the chemical
reactivity of the amine. When variations were made in the use of
rhodium source, for example, Wilkinson's catalyst, a dramatic drop
in product formation was observed by analytical HPLC analysis (data
not shown). Thereby leaving Rh(I)chloro(1,5-cyclooctadiene) and
triphenylphosphine the best catalyst mixture for the synthesis of
[urea-11C]-1, when using [11C]CO.Fig. 2. Immunohistochemical staining showed an elevated expression of Raf-1 kinase for the
the CD31 staining.3.2. Metabolite analysis
Since sorafenib is a registered pharmaceutical, in vivo metabolite
proﬁles are available for sorafenib when used as therapeutic at oral
doses of at least 50 mg daily and analyzedmultiple hours or even days
after administration. Since PET tracers are injected intravenous (iv), at
microdose levels and will be imaged within 1 h after administration, a
metabolite analysis using both [methyl-11C]-1 and [urea-11C]-1 was
required to ultimately decide which of both products is best suited to
be used as PET tracer. Therefore, [methyl-11C]-1 and [urea-11C]-1were
evaluated for their metabolic stability in vivo in Wistar rats. The
animals were injected (iv, tail vein) with 100–150 MBq of
[methyl-11C]-1 or [urea-11C]-1. At 15 and 45 min after injection the
rats were sacriﬁced and blood samples were obtained immediately
from the animals. Analysis of the blood plasma revealed a very high
percentage of intact tracer 45 min post-injection: 92.3% ± 4.5% for
[methyl-11C]-1 and 96.5% ± 0.9% for [urea-11C]-1, respectively.
Furthermore, both tracers showed less than 5% metabolized tracer
of apolar products, which could not be further characterized. The
HPLC retention time of the formed apolar metabolite was within
1 min of the parent tracer. Therefore, it is assumed that the formed
metabolite is sorafenib-N-oxide, which shows great similarities to theRXF393 and the FaDu xenografts. Only the RXF393 displayed a dense vascularization in
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that the use of either tracer will not lead to false-positive outcomes
due to binding of apolar radioactive metabolites to the investigated
target. Therefore, it was decided to continue in vivo tumor targeting
studies with the PET tracer that was most reliable in its synthesis:
[methyl-11C]-1.
3.3. Immunohistochemical staining of xenograft lines for
target expression
To evaluate the tumor targeting potential of [methyl-11C]-1, the
human xenografts RXF393, MDA-MB-231 and FaDu were used.Fig. 3. [18F]FDG and [methyl-11C]-1HRRT PET images of nude mice bearing RXF393 (A), FaDu
were injected with 10–15 MBq of [methyl-11C]-1 via the lateral tail vein and dynamic scann
tissue with red arrows. [methyl-11C]-1 scans were directly followed by injection with 10–15
intestines in all mice. Time-activity curves for RXF393 (D), FaDu (E) and MDA-MB-231-beari
Regions of interest were detected and drawn manually from the produced [18F]FDG imagesThese three xenografts were immunohistochemically characterized
for expression of Raf-1 kinase, the main target of sorafenib. The
observed differences in Raf-1 expression were remarkable between
the three xenografts investigated. RXF393 and FaDu both proved to
be strongly positive, while MDA-MB-231 tumors did not show Raf-1
expression (Fig. 2). Furthermore, CD31 staining was performed to
visualize tumor vascularization (Fig. 2). CD31 staining, to visualize
blood vessels, revealed that RXF393 had a dense vasculature
compared to FaDu and MDA-MB-231 (Fig. 2). Overall, though
immunohistochemical staining is not a quantitative method to
determine target expression levels, the Raf-1 expression was most
intense for RXF393. Furthermore, a high level of CD31 expression(B) andMDA-MB-231 xenografts (C) in their ﬂaks at time points 5, 30 and 60 min. Mice
ing was performed for 90 min. Tumors are indicated with white arrows and reference
MBq [18F]FDG for tumor localization. High uptake of [methyl-11C]-1 was visible in the

































































































Fig. 4. Biodistribution of [methyl-11C]-1 in RXF393 (n = 2, 4 tumors), FaDu (n = 3, 6 tumors) and MDA-MB-231 (n = 3, 6 tumors) tumor-bearing mice. Columns show the
percentage of injected dose per gram (%ID/g) per organ counted.
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might result in differences in [methyl-11C]-1 tumor accumulation
and retention.
3.4. PET imaging and biodistribution
PET studies with [methyl-11C]-1 as the tracer were performed
using dynamic scanning for 90 min of nude mice carrying either an
RXF393, an MDA-MB-231 or a FaDu xenograft on both ﬂanks (Fig. 3).
After PET scanning with [methyl-11C]-1, [18F]FDG images were
recorded to localize the tumors. Only RXF393 xenografts showed
signiﬁcant higher uptake when compared to the reference tissue
(Fig. 3A–C). In this study the reference tissue was manually
determined as an area close to the tumor only containing muscle
and skin, preferably the thigh of the mouse. Furthermore, the regions
of interest (ROI) of this reference area should absolutely not contain
any vital organs, since these vital organs might have tracer
accumulation resulting in an unreliable determination background
signal. For RXF393 a maximum accumulation of [methyl-11C]-1 of
2.52 ± 0.33 %ID/g at 7.5 min post-injection was observed, which was
signiﬁcantly higher compared to the reference tissue (p b 0.05).
Furthermore, also at 60 min post-injection tumor levels of
[methyl-11C]-1 were signiﬁcantly higher than in the reference area:
2.04 ± 0.37 versus 1.03 ± 0.17 %ID/g (Fig. 3D). For MDA-MB-231
and FaDu (Fig. 3E and F) slow accumulation of the tracer in the tumor
was observed; however, uptake was not signiﬁcantly higher com-
pared to reference tissue.
These obtained results by PET imaging were conﬁrmed in an ex
vivo biodistribution experiment in which the mice were dissected
5, 30 and 60 min post-tracer injection. The biodistribution was
assessed at 5, 30 and 60 min post-injection (p.i.) in nude mice
bearing RXF393, FaDu or MDA-MB-231 xenografts. In all cases liver
uptake of [methyl-11C]-1 was the highest of all organs and slowly
decreased over time. Blood levels of [methyl-11C]-1 were on
average 5 %ID/g at 5 min p.i. for all three xenograft lines, and
slowly decreased over time to an average of 3 %ID/g at 60 min p.i.
Tumor uptake levels of [methyl-11C]-1 in MDA-MB-231-bearing
mice slowly increased from 1.09 ± 0.09 to 2.11 ± 0.15 %ID/g in a
period of 5 till 60 min p.i. Similar tumor uptake levels of
[methyl-11C]-1 were observed in FaDu-bearing mice increasing
from 1.18 ± 0.12 to 1.73 ± 0.06 %ID/cc in a period of 5 till 60 min
p.i. Although some tumor accumulation was observed for both
MDA-MB-231 and FaDu, the uptake did not exceed the uptake of
some normal tissues like skin and muscle tissue (Fig. 4). RXF393-
bearing mice displayed relatively high tumor uptake levels of
[methyl-11C]-1 of 3.39 ± 0.15 %ID/g 5 min p.i., which slowly
decreases over time to 2.10 ± 0.09 %ID/g 60 min p.i. Uptake of
[methyl-11C]-1 was signiﬁcantly higher in the RXF393 xenograft
than in MDA-MB-231 and FaDu xenografts at 5 min p.i. (p b 0.01),
whereas no signiﬁcant differences in tracer uptake were observedfor the three xenograft lines at 30 and 60 min p.i. Thereby, in this
biodistribution the obtained data from the PET imaging study were
clearly conﬁrmed.
With current PET and biodistribution data available for
[methyl-11C]-1, it is tempting to assume that high accumulation
of [methyl-11C]-1 in the RXF393 xenograft at 5 min p.i. is related to
high Raf-1 and CD31 expression levels. The initial high tracer
uptake of [methyl-11C]-1 at 5 min p.i. can therefore most probably
be explained by the more dense vascularization of RXF393
compared to the other investigated tumor types. Furthermore, it
should be stated that sorafenib is a broad-spectrum TKI and
expression levels of other targets might inﬂuence the accumulation
and retention of the tracer as well. Furthermore, tumors often
express high levels of drug efﬂux transporters, for example, breast
cancer resistance protein (BCRP) and P-glycoprotein (Pgp), which
remove the drug from the cancer cell and cause drug resistance
[28,29]. It is known that sorafenib is prone to the drug efﬂux
transport system containing BCRP [30]. Therefore, this resistance
mechanism might have inﬂuenced the accumulation of
[methyl-11C]-1 as well, especially because of the microdose of
tracer used in the present study. Future research therefore needs to
focus on the inﬂuence of the drug efﬂux transport systems on the
[methyl-11C]-1 accumulation in the tumor. To this end,
[methyl-11C]-1 tumor accumulation will be investigated not only
upon microdosing but also upon administering therapeutic doses
of sorafenib and/or when blocking drug efﬂux transport systems
with, for example, tariquidar. In these studies [methyl-11C]-1 tumor
accumulation will be related to tumor response. Finally, even
though the observed tumor accumulation of [methyl-11C]-1 is not
as high as [18F]FDG (Fig. 3), [methyl-11C]-1 is a target-speciﬁc PET
tracer. Therefore, by further investigating the applicability of
[methyl-11C]-1, a PET tracer can be obtained of which tumor
accumulation can be related to sorafenib treatment response.4. Conclusions
Two novel reliable methods have been described for the synthesis
of [methyl-11C]-1 and [urea-11C]-1, using [11C]methyl iodide and
[11C]CO. In vivo metabolite analysis revealed that both products
were highly stable, and therefore both tracers can be used for PET
imaging studies without the possibility of false-positive or false-
negative results. Due to synthetic reliability it was decided to
continue in vivo research with [methyl-11C]-1. Tumor targeting of
[methyl-11C]-1 was only observed with PET imaging in the human
renal cell carcinoma xenograft RXF393 and these results were
conﬁrmed in a biodistribution study.
To conclude, [methyl-11C]-1 can be used as a PET tracer to conﬁrm
tumor targeting of sorafenib, and might have potential for prediction
of treatment outcome.
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